What Does Pionyr Immunotherapeutics Do?

Total employees35
HeadquartersBrisbane
Founded2015

Pionyr Immunotherapeutics, Inc., now a Gilead company, was a clinical-stage immuno-oncology company focused on developing a new generation of antibody-based therapeutics. Their innovative Myeloid Tuning™ approach aimed to alter the tumor microenvironment by reprogramming myeloid cells to enhance anti-tumor immunity. Pionyr's research centered on identifying and targeting novel immune regulatory mechanisms within the tumor stroma, with the goal of providing durable and clinically meaningful responses for cancer patients. The company was acquired by Gilead Sciences in June 2020 to bolster Gilead's immuno-oncology pipeline.

Where Is Pionyr Immunotherapeutics's Headquarters?

HQ Function

Served as the company's primary hub for research and development (R&D), clinical operations, and corporate administration, focusing on advancing their Myeloid Tuning™ platform.

Notable Features:

Located in a modern biotech park, likely equipped with advanced laboratory facilities suitable for antibody development and cancer research. Sierra Point is known for hosting numerous life science companies.

Work Culture:

As a biotech startup, Pionyr likely fostered a dynamic, science-driven, and collaborative environment with a strong emphasis on innovation, research excellence, and a mission-driven approach to cancer therapy.

HQ Significance:

The Brisbane headquarters was significant as the birthplace of Pionyr's Myeloid Tuning™ platform and the center of its efforts to develop novel cancer immunotherapies. Following its acquisition by Gilead, its assets and programs were integrated into Gilead's global R&D operations.

Values Reflected in HQ: The headquarters likely reflected values of scientific rigor, innovation, collaboration, and a patient-centric approach to drug discovery during its operational period.

Location:

As a focused biotechnology company prior to its acquisition by Gilead, Pionyr Immunotherapeutics' primary operations were centered in the United States. Its research and development efforts, while aimed at addressing global health challenges in oncology, were largely conducted from its California headquarters. Post-acquisition, its programs and technologies became part of Gilead's global oncology efforts.

Street Address:

2000 Sierra Point Parkway, Suite 600

City:

Brisbane

State/Province:

CA

Country:

USA

Where Else Does Pionyr Immunotherapeutics Operate Around the World?

No additional office locations available.

Buying Intent Signals for Pionyr Immunotherapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Pionyr Immunotherapeutics? Meet the Executive Team

As of April 2025, Pionyr Immunotherapeutics' leadership includes:

Steven P. James - Former President and Chief Executive Officer
Leonard H. Post, Ph.D. - Former Chief Scientific Officer
Evan Wadsworth, M.D. - Former Chief Medical Officer

Who's Investing in Pionyr Immunotherapeutics?

Pionyr Immunotherapeutics has been backed by several prominent investors over the years, including:

OrbiMed
New Enterprise Associates (NEA)
Sofinnova Ventures
SV Health Investors
Gilead Sciences (equity stake prior to full acquisition)
Ajax Dianthus
Vida Ventures
Osage University Partners

What Leadership Changes Has Pionyr Immunotherapeutics Seen Recently?

Hire1
Exits3

In the 12-18 months leading up to its acquisition by Gilead in June 2020, Pionyr Immunotherapeutics saw a key leadership appointment. Following the acquisition, its executive team transitioned as operations were integrated into Gilead.

Departures

Steven P. James, Transitioned from role following Gilead's acquisition.
Leonard H. Post, Ph.D., Transitioned from role following Gilead's acquisition.
Evan Wadsworth, M.D., Transitioned from role following Gilead's acquisition.

New Appointments:

Leonard H. Post, Ph.D., Dr. Leonard Post appointed as Chief Scientific Officer.

What Technology (Tech Stack) Is Used byPionyr Immunotherapeutics?

Discover the tools Pionyr Immunotherapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Pionyr Immunotherapeutics Email Formats and Examples

Prior to its acquisition by Gilead, Pionyr Immunotherapeutics likely used standard corporate email formats for its domain pionyrtx.com. While specific patterns are not publicly confirmed, a common format for companies of its type and size is the first initial followed by the last name.

[first_initial][last]@pionyrtx.com

Format

jdoe@pionyrtx.com (example for illustrative purposes)

Example

0 (domain inactive post-acquisition)%

Success rate

What's the Latest News About Pionyr Immunotherapeutics?

Gilead Sciences • June 23, 2020

Pionyr Immunotherapeutics news: Gilead Sciences Completes Acquisition of Pionyr Immunotherapeutics

Gilead Sciences announced the completion of its acquisition of Pionyr Immunotherapeutics Inc., a privately held company developing cancer immunotherapies that target myeloid cells. The acquisition adds Pionyr's pipeline programs, including PY314 and PY159, to Gilead's immuno-oncology portfolio....more

Business Wire (on behalf of Pionyr Immunotherapeutics) • April 2, 2020

Pionyr Immunotherapeutics news: Pionyr Immunotherapeutics Announces Collaboration with Gilead Sciences to Develop and Commercialize Novel Myeloid Tuning™ Therapies for Cancer

Pionyr Immunotherapeutics announced an agreement with Gilead Sciences, Inc. under which Gilead acquired a 49.9 percent equity interest in Pionyr and an exclusive option to acquire the remainder of Pionyr. The collaboration focused on advancing PY314 and PY159, first-in-class antibody programs....more

FierceBiotech • November 6, 2019

Pionyr Immunotherapeutics news: Pionyr lures new CSO from Achaogen, inks Ichnos deal to take on cancer

Pionyr Immunotherapeutics hired Leonard Post, Ph.D., as its new chief scientific officer. Post previously served as CSO at Achaogen. Pionyr also announced a manufacturing deal with Ichnos Sciences for its lead programs PY314 and PY159....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Pionyr Immunotherapeutics, are just a search away.